Fortune 500 pharmaceutical company

December 1, 1988

Representation of a Fortune 500 pharmaceutical company in connection with its acquisition of a developer and manufacturer of catheter systems, pursuant to a reverse triangular merger. Total consideration was approximately $120 million.
Back to top